Margy Meislin

Lupus Research Alliance and Clinical Affiliate Lupus Therapeutics Selected as Inaugural Strategic Collaborators with Vie Ventures to Advance Innovative Autoimmune Therapies   

|

The Lupus Research Alliance and clinical affiliate Lupus Therapeutics are proud to be selected as inaugural collaborators of the new life sciences investment firm, Vie Ventures.   Vie Ventures is focused on bridging venture capital and disease philanthropy. The organization is concentrating on advancing late-stage, breakthrough therapies for autoimmune diseases and other immune system disorders where … Lupus Research Alliance and Clinical Affiliate Lupus Therapeutics Selected as Inaugural Strategic Collaborators with Vie Ventures to Advance Innovative Autoimmune Therapies   

FDA Accepts Application for Potential Treatment for Lupus Nephritis, Gazyva®

|
Breaking news: Gazyva for Lupus Nephritis

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, is eager to share exciting news. The U.S. Food and Drug Administration accepted the supplemental Biologics License Application (sBLA) from Genentech for Gazyva® (obinutuzumab) as a potential treatment of lupus nephritis. The acceptance is based on results from the Phase 3 REGENCY study showing improved complete renal … FDA Accepts Application for Potential Treatment for Lupus Nephritis, Gazyva®

Obinutuzumab Showed Significantly Positive Results in Published Phase III Lupus Nephritis Study

|
Breaking News

Exciting breaking news: A paper published in the highly prestigious journal New England Journal of Medicine and presented at the World Congress of Nephrology reported that results of the Phase III REGENCY trial found that among people with active lupus nephritis, Gazyva® (obinutuzumab) plus standard therapy demonstrated statistically significant and clinically meaningful improvement in the … Obinutuzumab Showed Significantly Positive Results in Published Phase III Lupus Nephritis Study